Denosumab is a monoclonal antibody against the anti-receptor activator of nuclear factor-kappa β ligand approved for the treatment of osteoporosis and the prevention of complications of skeletal metastases [17]. The gene discussed is TNFSF11; the disease is osteoporosis.